Breaking Finance News

Roth Capital covered AcelRx (NASDAQ:ACRX), boosting its stock price target to $15.00 today

Indicating a possible upside of 3.57%, Roth Capital bumped the target price of AcelRx (NASDAQ:ACRX) to $15

Showing a price of $3.28, AcelRx (NASDAQ:ACRX) traded 9.76% higher on the day. With the last close down 9.03% from the two hundred day moving average, compared with the S&P 500 Index which has fallen -0.01% over the same period. ACRX has logged a 50-day average of $3.39 and 200-day average of $3.30. 4,326,979 shares of the stock traded hands, up from ann avg. trading volume of 350,938

See Graph Below:


AcelRx has a one-year low of $2.40 and a 52 week high of $5.88 . The company’s market capitalization is presently $0.0.

In addition to Roth Capital reporting it’s price target, a total of 4 brokers have released a report on ACRX. The consensus target stock price is $7.63 with one firm rating the stock a strong buy, three analysts rating the company a buy, two analyts rating the stock a hold, 0 rating the stock to underperform, and lastly 0 analystsrating the stock as sell.

More About AcelRx (NASDAQ:ACRX)

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product candidates include ARX-04, Zalviso, which utilize sublingual sufentanil, delivered through a non-invasive route of administration, and ARX-03. ARX-04 is meant for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in medically supervised settings. Zalviso is meant for the management of moderate-to-severe acute pain in hospitalized adult patients. ARX-03 provides mild sedation, anxiety reduction and pain relief for patients undergoing painful procedures in a physician’s office. It also includes ARX-02, and which is meant for the treatment of patients who suffer from breakthrough pain (BTP) due to cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *